Table 2_A Bayesian network meta-analysis: evaluating the efficacy and safety of targeted t

A Bayesian network meta-analysis comparing the efficacy and safety of targeted therapies for metastatic or advanced radioiodine-refractory differentiated thyroid cancer. The analysis is based on 9 randomized controlled trials involving 1,760 patients, evaluating outcomes including progression-free survival and objective response rate. The dataset was created by Pin Wang and last updated in March 2026.

Use Cases

• Compare the progression-free survival benefit of different tyrosine kinase inhibitors based on reported hazard ratios.
• Rank treatments for safety based on the reported surface under the cumulative ranking curve values for adverse events.
• Analyze time-dependent efficacy patterns of therapies like apatinib based on the described waning benefit after 6-9 months.
• Assess the objective response rate of treatments like lenvatinib based on the reported odds ratio.

Strengths

• Analysis is based on 9 randomized controlled trials, a standard for high-quality evidence.
• Includes data from 1,760 patients with radioiodine-refractory differentiated thyroid cancer.
• Uses Bayesian network meta-analysis, a statistically rigorous method for comparing multiple treatments.
• Reports specific statistical results like hazard ratios, odds ratios, and SUCRA values for ranking.

Limitations

• Row count and column-level documentation are absent; field semantics must be inferred after download.
• The dataset is small (40.5 KB), indicating it contains summary-level analysis results rather than patient-level data.
• Data may reflect bias inherent to the specific clinical trials included in the meta-analysis.

Provenance

Source

Systematic search of six electronic databases, as described in the methods.

Collection Method

Bayesian network meta-analysis of randomized controlled trials.

Freshness

Last updated 2026-03-18 07:35:09; freshness should be verified.